![](https://www.discoverx.com/content/uploads/2024/03/Obesity-Diabetes_Landing-Page-Header_GI-thumb.jpg)
Assays to interrogate the MOA of GLP-1, GIP, and GCG receptors targeting therapeutics to accelerate obesity and type-2 diabetes drug…
Read MoreShowing 13–24 of 25 results
Assays to interrogate the MOA of GLP-1, GIP, and GCG receptors targeting therapeutics to accelerate obesity and type-2 diabetes drug…
Read MoreAccelerate cancer immunotherapeutic discovery & development with cell-based, clinically relevant assays
Read MoreQuantitative cell-based assays to identify pharmacochaperones that stabilize & correct disease-relevant mutant GPCRs, ion channels, or transporters
Read MoreOver 500 high-quality & purified recombinant kinases, phosphatases, & epigenetic & ubiquitin proteins
Read MoreCell-based assays to confirm compound cell entry, protein target binding, screen & rank inhibitors, & measure cellular potencies
Read MoreRapid cell-based assays for detecting protein turnover induced by targeted degrader molecules, such as PROTACs
Read MoreComplete set of parental cell lines, vectors, kits, & retroparticles to build your own stable cell lines & cell-based assays
Read MoreScreening cell-based translocation assays for analyzing the movement of proteins to multiple membrane compartments within the cell
Read MoreThank you for visiting our website. 1 Controller information The entity in charge of the control of any information obtained…
Read MoreEurofins DiscoverX’s simple, robust, & homogeneous detection assay system to perform binding & functional screens, screen molecules, & more
Read MoreNorth America Eurofins DiscoverX® Products LLC 42501 Albrae StreetFremont, CA 94538United StatesPhone: (510) 979-1415Toll-free: (866) 448-4864 (US only)Email: DiscoverXCustomerServices@discovery.eurofinsus.com Europe Eurofins…
Read More